AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06487104 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TrachPhone HME
Description: Use of TrachPhone HME for humidification of inhaled air in tracheostomized patients.~The TrachPhone HME is an HME specifically designed for tracheostomy patients.
Study NCT06487104 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: External Humidifier (Usual Care)
Description: Usual care routines using an External Humidifier for humidification of inhaled air in tracheostomized patients.
Study NCT05922501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: An IgG1-derived monoclonal antibody that targets CD38 proteins, administered intravenously.
Study NCT05922501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: An antibody-drug conjugate that is the combination of an antibody targeting BCMA and a drug, administered intravenously.
Study NCT05922501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: An immunomodulatory agent, capsule taken orally.
Study NCT05922501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: A glucocorticoid which is a substance that stops inflammation cause by immune system disorders, tablet taken orally.
Study NCT05177887 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Traumacel PULVIS, Traumacel ENDO Applicator
Description: Haemostatic plant polysaccharide powder made of the oxidized cellulose with flexible applicator (38 cm).
Study NCT05986643 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exergame+Neurofeedback
Description: Electroencephalography (EEG) is a device that measures the electrical activity of the brain (brain waves). There are several frequencies of brain waves when we are awake; alpha (medium), beta (fast), and theta (slow). Alpha frequencies of brain activity are linked to maintaining balance, with more alpha activity being associated with poorer balance. EEG neurofeedback treatment involves placing electrodes on a person's head to monitor and change brain activity by giving cued audio or visual feedback. It has been used in PwP to show improvements in balance and walking. Other preliminary research in PwP has shown that exercise can also improve balance.
Study NCT05986643 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Exergame [alone]
Description: The exergame, delivered in virtual reality, involves travelling down a road (to give optic flow) whilst dodging balls that move towards the participant by either shifting their body either to the left or right. They are also be instructed to stand still and catch stars that appear and these will be used to score points and are associated with a monetary reward, ensuring motivation.~This group will receive SHAM feedback.
Study NCT05618912 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing
Description: A single hydrocolloid dressing will be applied to the surgical site for 7 days following dermatologic surgery
Study NCT04694001 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Use of the Atalante exoskeleton
Description: A session includes stand-up, walks, exercises with or without the assistance of the exoskeleton, rotation, side and back step, squat and sitting.
Study NCT05618912 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Petrolatum jelly dressing
Description: The patient with the control wound will be covered with petrolatum jelly during this time period, which has to be re-applied daily.
Study NCT06687655 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone-IQ
Description: This is a crossover study where participants will ingest either Ketone-IQ for 2 nights, or placebo for 2 nights before sleep. This is the Ketone-IQ (1,3 Butanediol) intervention.
Study NCT06687655 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: This is a crossover study where participants will ingest either Ketone-IQ for 2 nights, or placebo for 2 nights before sleep. This is the Placebo intervention.
Study NCT06703229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The Transversus Abdominis Plane (TAP) block
Description: or injectate preparation, utilizing ultrasound guidance while the patient was supine. In the D1 group, patients were administered 20 mL of 0.25% isobaric bupivacaine with 0.5 mcg/kg of dexmedetomidine.
Study NCT06703229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The transverse abdominis plane (TAP) block
Description: Patients in the D2 group received 20 mL of 0.25% isobaric bupivacaine with 1 mcg/kg of dexmedetomidine.
Study NCT06716021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The formulation of placebo will consist of water, sodium acetate, disodium EDTA, and sulfuric acid to reproduce the same pH as the etripamil formulation.
Study NCT06716021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etripamil
Description: The formulation of etripamil is for IN administration and will consist of etripamil, water, acetic acid, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid. The dose of etripamil to be evaluated in this study is 70 mg with an optional second dose of 70 mg 10 minutes after the first dose if symptoms persist.
Study NCT06728631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candonilimab and ATRA
Description: Candonilimab at a dose of 6mg/kg IV Q3W will be administered until a maximum treatment duration of 1 year. All-trans retinoic acid will be administered at a dose of 25mg/m² twice daily on days 1-14, with a treatment cycle of 21 days, until a maximum treatment duration of 6 months, or until the occurrence of oral cancer or other malignancies, death, intolerable toxicity, withdrawal of informed consent, or any other reasons specified in the protocol.
Study NCT06728631 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: other treatment or observation
Description: other treatment other than Candonilimab/ATRA or observation
Study NCT06727695 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioStrength Intervention
Description: Participants in the Intervention Group will undergo BioStrength training using Technogym equipment. The intervention will last for 12 weeks, with sessions conducted 3 times per week
Study NCT06727695 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional training
Description: Participants in the Active Comparator group will undergo a conventional strength training program using standard gym machines. Training sessions will occur 3 times per week for 12 weeks. The goal is to compare the outcomes of BioStrength training with traditional strength training.
Study NCT06729359 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography of the abdomen and pelvis
Description: ultrasonography of the abdomen and pelvis using a 3.5mhz abdominal probe
Study NCT06332560 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory diet (DI)
Description: 12-week personalized dietary advice based on the Dutch Dietary Guidelines under the guidance of a dietician.
Study NCT06332560 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: Seven individual sessions led by a psychotherapist. The content of the CBT will be psycho-education regarding pain mechanisms and DI.
Study NCT05478759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal affect recognition training
Description: 8 session, trains participants to recognize expression of emotion from a variety of stimuli, including dynamic stimuli (e.g., video instead of still pictures) and it employs both facial and vocal examples of emotion expression.
Study NCT05478759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Training
Description: computerized attention drill training
Study NCT05478759 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Brain Health Workshop
Description: an education presentation on brain function and cognitive principles of learning with homework and quizzes on information covered.
Study NCT05478759 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: National Geographic Movies
Description: participant will watch movies and answer questions after
Study NCT05655273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: Participants randomized to the Prograf (control) arm will continue with their current twice daily dosing of Prograf.
Study NCT05655273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Envarsus
Description: Participants randomized to Envarsus arm will have their current daily dose of Prograf converted to once-daily Envarsus dose according to the following ratio: 0.7 x the current daily Prograf dose. Envarsus is available in 3 dose strengths- 0.75mg, 1.0mg, and 4.0mg. The actual dose of Envarsus will be rounded to an amount that can be administered using the above tablet strengths.
Study NCT05996432 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Participants will undergo Magnetic Resonance Imaging
Study NCT05996432 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Participants will undergo Positron Emission Tomography
Study NCT05996432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluoromisonidazole
Description: Given by IV
Study NCT05249647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument based Fascial abrasion technique
Description: Participants were in a comfortable position during treatment. Emollient (anti-allergic) was applied to prevent skin irritation prior to Fascial Abrasion application. Each session included 1 minute of sweeping (longitudinal strokes performed parallel to the muscle fibers similar to compression with oscillations) directly over the Myofascial trigger points, 2 minutes of fanning (one end of the instrument was held in place \& the other end moved through a semicircular pattern similar to petrissage) and concluded with 1 min of sweeping. Fascial Abrasion tool was washed in alcohol-based sanitizer before and after every treatment session and all norms of COVID-19 precautions were maintained. Myofascial trigger points were marked with a 1×1 cm piece of tape/under wrap to confirm consistency of subsequent treatments.
Study NCT05249647 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial release technique
Description: All participants will get Conventional therapy i.e heating pad for 10 minutes. For the application of technique, the patient position will be supine lying with head fully supported on therapist hands and therapist places 3 middle fingers just inferior to the nucle line, lifts the finger tips towards the ceiling while resting the head on the table and then therapist applied a gentle upward pull. This procedure done for 2-3 minutes, 5-7 repetitions, 3 sessions per week on alternate days given for 6 weeks.
Study NCT05212727 — intervention group
Intervention type: DEVICE
Intervention: Eye-tracking
Description: Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
Study NCT04942366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: HIIT using treadmill four sets of 4 minute interval session (at 90%-95% of the individual HR max calculated by using the karvonen method) and each set will be followed by three minute of moderate intensity exercise (at 70% of individual HR max).
Study NCT04942366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: Strength training will be performed thrice a week, each session will consist of eight dynamic drills.
Study NCT06049589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coconut Oil
Description: Coconut oil rinsing
Study NCT06049589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: Chlorhexidine rinsing
Study NCT06049589 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water mouthwash
Description: Control with water rinsing
Study NCT04805671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADG20
Description: Single dose of ADG20
Study NCT04805671 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Single dose of normal saline
Study NCT05043116 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol D3
Description: 2000 IU of Vitamin D provided as oral suspension for one year
Study NCT05043116 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo suspension
Description: Oral suspension with no active substance tasting like the active supplement.
Study NCT04915560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected T-shirt
Description: Ware of a connected T-shirt
Study NCT05619731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatric oncology tele-consultation and pharmaceutical tele-expertise
Description: tele consultation
Study NCT05460546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jincaopian Tablets high dose
Description: Jincaopian Tablets 0.2g tid p.o.
Study NCT05460546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jincaopian Tablets low dose
Description: Jincaopian Tablets 0.1g tid p.o.
Study NCT05460546 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tid p.o.
Study NCT05550350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexycu
Description: 103.4 mcg/mcl dexamethasone: equivalent dexamethasone dose: 517 mcg
Study NCT05550350 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/Vehicle
Description: Placebo/vehicle, 0 mcg/mcl dexamethasone: equivalent dexamethasone dose: 0 mcg
Study NCT04754893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Healthdot application
Description: Healthdot device is applied on subject's chest after surgery
Study NCT05500677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine topical
Description: Lidocaine spray, which is a quick and easy-to-use topical local anesthetic, will be applied as a puff to the painful area.
Study NCT05483413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: progressive relaxation exercises
Description: Progressive relaxation exercises are a cognitive behavioral technique that provides relaxation in the muscles that individuals can do alone.
Study NCT05909826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: 70 mg/m2 IV days 1, 8 and 15, every 4 weeks
Study NCT05909826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg PO days 1 to 21, every 4 weeks
Study NCT05909826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40mg PO or IV days 1, 8, 15, and 22, every 4 weeks
Study NCT05781191 — intervention group
Intervention type: BIOLOGICAL
Intervention: COMIRNATY
Description: Booster (3rd) dose of COMIRNATY Seasonal dose of influenza vaccination based on patient's individual risk factors
Study NCT06479031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: Occupational Therapy intervention, once a day, for 5 days, for 40 minutes each session.
Study NCT04921475 — intervention group
Intervention type: DEVICE
Intervention: Regional oxygen saturation monitoring
Description: Regional oxygen saturation of kidney is monitored using near infrared spectroscopy
Study NCT06214741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: survodutide
Description: once weekly subcutaneous injection
Study NCT06214741 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BI 456906
Description: Once weekly subcutaneous injection
Study NCT05282628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Building Better Brains and Behavior program (B4 Preterm)
Description: The program couples online learning modules with video conferencing sessions with a trained therapist to review skills and practice implementing the skills with live coaching. Online modules include didactic content, video clips of parents modeling the skills, and exercises. Parents will complete intervention modules sequentially in conjunction with scheduled 1:1 videoconference sessions with a trained therapist. Videoconference sessions with the therapist will be scheduled weekly, once parents have completed their modules. During these sessions, the therapist will review the online materials and provide active coaching to the parent on how to use the skills with their child (e.g., labeled praise, reflective responses). Each session follows a manualized therapy protocol to optimize content fidelity. Parents will be instructed to practice the parenting skills for 5 minutes each day to promote mastery in the home environment.
Study NCT05222555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: tafasitamab will be administered intravenously at protocol defined timepoints
Study NCT05222555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: lenalidomide will be administered orally at protocol defined timepoints
Study NCT05572645 — intervention group
Intervention type: DRUG
Intervention: Pyrotinib Plus Trastuzumab
Description: treatment based on Pyrotinib(320-400 mg, po, qd) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)
Study NCT05572645 — intervention group
Intervention type: DRUG
Intervention: Pertuzumab Plus Trastuzumab
Description: treatment based on Pertuzumab(840mg q3w, and then 420 mg q3w) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)
Study NCT05465447 — intervention group
Intervention type: DEVICE
Intervention: subjective refraction
Description: Short-term postoperative (1-3 months) and long-term postoperative (3-5 years) subjective optometry results were measured by subjective refraction.
Study NCT05294120 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reflectance ConfocaL Microscopy And Optical Coherence Tomography Guided
Description: Patients will undergo RCM/OCT with an imaging specialist in the Dermatology Service.~This is not expected to take longer than 30 minutes. Prior to imaging, a digital photograph will be taken of the biopsy proven BCC.
Study NCT05294120 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: After the completion of skin imaging, patients will undergo simulation and tumor radiotherapy. An equivalent total dose in 2 Gy fractions (EQD2) of 45-46 Gy will be delivered for treatment.
Study NCT04652557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fampridine SR
Description: Fampridine SR is an inhibitor of voltage gated potassium channels and is approved in Switzerland for treatment of gait problems in patients with Multiple Sclerosis (MS).
Study NCT04652557 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: no active component
Study NCT06005363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: dexmedetomidine infusion
Study NCT06005363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anesthesia depth monitoring
Description: intraoperative anesthesia depth monitoring to keep BIS 40-60
Study NCT04462783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptoms entered into the CovidX application
Description: Participants are asked to enter symptoms into the CovidX application at least daily for 30 days. Additionally, they will enter demographic information and some survey information will be collected.
Study NCT06381180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol
Description: Plant cannabis that will be vaporized
Study NCT06381180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Plant cannabidiol that will be vaporized
Study NCT06381180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Plant will be vaporized.
Study NCT06080009 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: exome sequencing (retrospective) and exome and methylome sequencing (prospective)
Description: Three to nine sections will be used as the source of DNA for each tumor. The pathologist will identify and separate tumor tissue from normal tissue, and the two DNAs will be sequenced separately. Variants obtained from tumor and normal tissue will be compared, with different outcomes. Expected in this way are 1) somatic/tumor-specific variants (which are absent in normal tissue), 2) variants lost during tumor evolution due to segmental chromosomal deletion or other mechanisms that cause loss of heterozygosity. Using these two classes of variants, a clustering analysis will be performed at the end of the sequencing project to better define the phenotype and molecular signature of the tumors. In the prospective part of the project, the new tumors will be frozen fresh. This resource will allow methyloma analysis to be performed.
Study NCT05504096 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Actxa BGM Tracker (GLO2)
Description: Wrist-worn wearable
Study NCT05504096 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SVT In-Ear Prototype (IEP)
Description: In-Ear wearable
Study NCT05662020 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)
Description: 9-19 years group (3 doses) and 20-26 years group (3 doses) will be vaccinated at months 0, 2, 6. 9-14 years group (2 doses) will be vaccinated at months 0, 6.